Fabry Disease: Further Considerations in Selecting a Treatment Option

 
Compartilhar
 

Manage episode 302757485 series 1103955
Por ReachMD descoberto pelo Player FM e nossa comunidade - Os direitos autorais são de propriedade do editor, não do Player FM, e o áudio é transmitido diretamente de seus servidores. Toque no botão Assinar para acompanhar as atualizações no Player FM, ou copie a feed URL em outros aplicativos de podcast.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph William Ray, MD
Fabry disease is a progressive, genetic disorder that can cause multisystemic damage and reduce life expectancy when left undiagnosed and unmanaged, making the timely and appropriate management of Fabry disease essential. Recent clinical outcome data and real-world evidence led to the approval of Fabrazyme, a treatment option for Fabry disease. Joining Dr. Charles Turck to share that data is Dr. Joseph William Ray, an Associate Professor of Pediatrics and Director of Medical Genetics at the University of Texas Medical Branch.

For more information, please visit www.fabrazyme.com/hcp.

MAT-US-2107750-v1.0-08/2021

447 episódios